Imagine a pharmaceutical company spends nearly four years touting a ground-breaking new medicine that will cure all diseases.
Early evidence supporting those claims is limited, and massive questions remain, but the company continues to make progress. Criticism and concerns, while addressed, don’t slow its aggressive push.
After all, investors believe this is the real deal. (Or at least a really good bet.)
And then right before the pharma company unveils its fancy new drug, it gives a shocking update: It turns out the medicine could also be a poison. So, for the safety of all involved, progress in the space needs to be slowed to ensure things…
